Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Positron Emission Tomography
78%
Positron Emission Tomography-Computed Tomography
68%
Polyethylene Terephthalate
56%
Neoplasm
54%
Fluorodeoxyglucose F 18
39%
Radiation Therapy
38%
Cervical Cancer
35%
Diseases
31%
Neuroendocrine Tumor
24%
Pelvis
23%
Gallium 68
22%
Fluorine-18
22%
Tumor
21%
Carcinoma
20%
Magnetic Resonance Imaging
20%
Computer Assisted Tomography
18%
Fluorodeoxyglucose
18%
Prostate Cancer
18%
Recurrent Disease
18%
Cancer
17%
Scintigraphy
16%
Chemotherapy
15%
Brachytherapy
15%
Metastatic Carcinoma
15%
Overall Survival
14%
Heart Muscle Blood Flow
13%
Malignant Neoplasm
12%
Lutetium 177
11%
Oncology
11%
Lymph Node
11%
Prostate Specific Membrane Antigen
11%
Somatostatin Receptor
10%
Nuclear Medicine
10%
Radioactive Tracer
10%
Cervix
10%
Technetium-99
10%
Coronary Artery Disease
10%
Radionuclide Therapy
9%
Peptide Receptor
9%
Molecular Imaging
9%
Glucose
9%
Treatment Planning
8%
Uterine Cervix
8%
Non Small Cell Lung Cancer
8%
Biological Marker
8%
Standardized Uptake Value
8%
Single-Photon Emission Computed Tomography
8%
Uterine Cervix Carcinoma
8%
Clinical Trial
8%
Lung
7%
Biopsy Technique
7%
Lymph Node Metastasis
7%
Treatment Response
7%
Chemoradiotherapy
7%
Distant Metastasis
7%
Breast Cancer
7%
Progression Free Survival
7%
Uterine Cancer
7%
Primary Tumor
7%
Intensity Modulated Radiation Therapy
7%
Radiopharmaceutical
7%
Pediatrics
7%
Prognostic Factor
7%
Positron Emission Tomography - Magnetic Resonance Imaging
6%
Radioisotope
6%
Radiology
6%
Heart Muscle Perfusion
6%
Coronary Circulation
6%
Amyloid Protein
6%
Dosimetry
6%
Tetraxetan
6%
Paraaortic Lymph Node
5%
Pulmonary Embolism
5%
Drug Megadose
5%
Disease Free Survival
5%
Cardiovascular System
5%
Low Drug Dose
5%
Keyphrases
Positron Emission Tomography/computed Tomography (PET/CT)
100%
Tumor
41%
Cervical Cancer
36%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
26%
Cervical Carcinoma
22%
Irradiation
19%
18F-fluorodeoxyglucose (18F-FDG)
18%
Computed Tomography
18%
Neuroendocrine Tumor
17%
Radiation Therapy
16%
18F-FDG PET-CT
15%
Myocardial Blood Flow
14%
Overall Survival
14%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
14%
SUVmax
13%
Radiotherapy
13%
Brachytherapy
13%
Fluorodeoxyglucose
12%
Prostate-specific Membrane Antigen
11%
Lutetium-177 (177Lu)
11%
Standardized Uptake Value
11%
Cardiac Magnetic Resonance Imaging (cMRI)
11%
Single-photon Emission Computed Tomography (SPECT)
11%
Prostate Cancer
9%
Peptide Receptor Radionuclide Therapy
9%
PET-MRI
9%
Technetium-99m
9%
Distant Metastasis
9%
Nuclear Medicine
9%
Radiopharmaceuticals
9%
Liver
9%
Chemotherapy
9%
PET Imaging
9%
Molecular Imaging
8%
Progression-free Survival
8%
Prognostic Factors
8%
Positron Emission Tomography Imaging
7%
Scintigraphy
7%
Primary Tumor
7%
Non-small Cell Lung Cancer (NSCLC)
6%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
6%
Radiation Dose
6%
Breast Cancer
6%
Pelvis
6%
Dosimetry
6%
Gallium-68
6%
Oncologic
6%
Myocardial Flow Reserve
6%
Metastasis
6%
Theranostics
6%
Coronary Artery Disease
6%
Positron Emission tomography-CT
6%
Disease-free Survival
6%
Somatostatin Receptor
6%
Tumor Volume
5%
Lung
5%
Radiation Therapy Oncology Group
5%
Intensity-modulated Radiation Therapy
5%
Clinical Application
5%
Intracavitary
5%
Whole-body
5%
Prostate-specific Membrane Antigen Positron Emission Tomography
5%
Malignancy
5%
Radionuclides
5%
95% Confidence Interval
5%
Stage IB
5%
Tumor Response
5%
Patient Management
5%
Clinical Outcomes
5%
Perfusion
5%
Phase I Study
5%
Lymph Node Metastasis
5%
Fluoro
5%
High Dose
5%
Endometrial Cancer
5%
Prostate Cancer Patients
5%
Imaging Modalities
5%
Radiotracer
5%
PET Image
5%
Oncology
5%
Concurrent Chemotherapy
5%
Myocardial Perfusion
5%
Metastatic Disease
5%
Clinical Trials
5%